Market Announcement

17 November 2026

Microba Life Sciences Limited (ASX: MAP) – Suspension from Quotation

The securities of Microba Life Sciences Limited ('MAP') will be suspended from quotation immediately under Listing Rule 17.2 at the request of MAP, pending the release of an announcement by MAP.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in MAP's request for voluntary suspension; or
- the release of the announcement to the market.

MAP's request for voluntary suspension is attached below for the information of the market.

Issued by

ASX Supervision

ASX Announcement
17 November 2026

Ms Renee Hutchens
Adviser, ASX Listings Compliance (Sydney)
20 Bridge Street,
SYDNEY, NSW 2000

By email: tradinghaltssydney@asx.com.au

Request for Voluntary Suspension – Microba Life Sciences Ltd (ASX: MAP)

Microba Life Sciences Ltd (ASX: MAP) (**Microba**) requests a voluntary suspension of all its quoted securities to apply from the commencement of trading on Tuesday, 17 November 2026.

At its request, Microba entered a trading halt on Friday, 13 November 2026, pending an announcement regarding proposed material changes to the terms of the proposed merger between Microba and Genetic Signatures Ltd (**Proposed Merger**).

Following discussions between Microba and Genetic Signatures Ltd, the revised indicative terms of the Proposed Merger, while considered generally commercially acceptable to the Microba Board, are on terms such that Microba will be unable to satisfy the conditions to complete Tranche 2 of the institutional placement, announced to the ASX on 20 October 2026 (**Placement**).

The impact of the Placement not proceeding is that Microba will not have the financial capacity to complete the Proposed Merger and will have a reduced cashflow runway. Microba is currently assessing its cashflow position and is exploring its options for alternative funding (**Stated Purpose**). Until this has been determined, Microba considers that continued trading in its securities is likely to be materially prejudicial to its ability to complete any transaction critical to its continued financial viability.

In accordance with ASX Listing Rule 17.2, Microba provides the following information:

(a) Microba requests the voluntary suspension be put in place until the earlier of commencement of trading on Monday, 23 November 2026 or such time that Microba makes an announcement to the market in relation to the Stated Purpose above;

(b) Microba is not aware of any reason why the voluntary suspension should not be granted; and

(c) Microba is not aware of any other information necessary to inform the market about the voluntary suspension.

Yours sincerely,

James Heath
CFO & Company Secretary

This announcement has been authorised for release by the Board of Directors.

For further information, please contact:

About Microba Life Sciences Limited
Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com